243 related articles for article (PubMed ID: 26641067)
1. Fibroblasts prolong serum prostate-specific antigen decline after androgen deprivation therapy in prostate cancer.
Sasaki T; Ishii K; Iwamoto Y; Kato M; Miki M; Kanda H; Arima K; Shiraishi T; Sugimura Y
Lab Invest; 2016 Mar; 96(3):338-49. PubMed ID: 26641067
[TBL] [Abstract][Full Text] [Related]
2. Prostate fibroblasts enhance androgen receptor splice variant 7 expression in prostate cancer cells.
Sasaki T; Yoshikawa Y; Kageyama T; Sugino Y; Kato M; Masui S; Nishikawa K; Inoue T
Prostate; 2023 Mar; 83(4):364-375. PubMed ID: 36479717
[TBL] [Abstract][Full Text] [Related]
3. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
Gleave ME; Hsieh JT; Wu HC; von Eschenbach AC; Chung LW
Cancer Res; 1992 Mar; 52(6):1598-605. PubMed ID: 1371718
[TBL] [Abstract][Full Text] [Related]
4. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.
Choueiri TK; Xie W; D'Amico AV; Ross RW; Hu JC; Pomerantz M; Regan MM; Taplin ME; Kantoff PW; Sartor O; Oh WK
Cancer; 2009 Mar; 115(5):981-7. PubMed ID: 19152438
[TBL] [Abstract][Full Text] [Related]
5. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
6. A novel regulation of PSMA and PSA expression by Q640X AR in 22Rv1 and LNCaP prostate cancer cells.
Ben Jemaa A; Sallami S; Céraline J; Oueslati R
Cell Biol Int; 2013 May; 37(5):464-70. PubMed ID: 23418075
[TBL] [Abstract][Full Text] [Related]
7. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW
J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045
[TBL] [Abstract][Full Text] [Related]
8. Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
Eur Urol; 2014 Mar; 65(3):620-7. PubMed ID: 23245686
[TBL] [Abstract][Full Text] [Related]
9. Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy.
de Crevoisier R; Slimane K; Messai T; Wibault P; Eschwege F; Bossi A; Koscielny S; Bridier A; Massard C; Fizazi K
Ann Oncol; 2010 Apr; 21(4):808-814. PubMed ID: 19825885
[TBL] [Abstract][Full Text] [Related]
10. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891).
Studer UE; Collette L; Whelan P; Albrecht W; Casselman J; de Reijke T; Knönagel H; Loidl W; Isorna S; Sundaram SK; Debois M;
Eur Urol; 2008 May; 53(5):941-9. PubMed ID: 18191322
[TBL] [Abstract][Full Text] [Related]
11. Cessation of Primary Androgen Deprivation Therapy for Men With Localized Prostate Cancer.
Fujimoto N; Kubo T; Tomisaki I
Clin Genitourin Cancer; 2015 Aug; 13(4):359-363. PubMed ID: 25907231
[TBL] [Abstract][Full Text] [Related]
12. Assessment of oligometastasis status of prostate cancer following combined robot-assisted radical prostatectomy and androgen deprivation versus androgen deprivation therapy alone using PSA percentage decline rate.
Li X; Xi H; Cheng X; Yu Y; Zhang C; Wang G; Zhou X
Front Endocrinol (Lausanne); 2023; 14():1123934. PubMed ID: 36843605
[TBL] [Abstract][Full Text] [Related]
13. Loss of Fibroblast-Dependent Androgen Receptor Activation in Prostate Cancer Cells is Involved in the Mechanism of Acquired Resistance to Castration.
Ishii K; Matsuoka I; Sasaki T; Nishikawa K; Kanda H; Imai H; Hirokawa Y; Iguchi K; Arima K; Sugimura Y
J Clin Med; 2019 Sep; 8(9):. PubMed ID: 31484364
[TBL] [Abstract][Full Text] [Related]
14. Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer: A retrospective study.
Ji G; Song G; Huang C; He S; Zhou L
Medicine (Baltimore); 2017 Sep; 96(36):e7823. PubMed ID: 28885333
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditions.
Røe K; Seierstad T; Kristian A; Mikalsen LT; Mælandsmo GM; van der Kogel AJ; Ree AH; Olsen DR
Neoplasia; 2010 Oct; 12(10):818-25. PubMed ID: 20927320
[TBL] [Abstract][Full Text] [Related]
16. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study.
Matsubara N; Chi KN; Özgüroğlu M; Rodriguez-Antolin A; Feyerabend S; Fein L; Alekseev BY; Sulur G; Protheroe A; Li S; Mundle S; De Porre P; Tran N; Fizazi K
Eur Urol; 2020 Apr; 77(4):494-500. PubMed ID: 31843335
[TBL] [Abstract][Full Text] [Related]
17. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.
Harshman LC; Chen YH; Liu G; Carducci MA; Jarrard D; Dreicer R; Hahn N; Garcia JA; Hussain M; Shevrin D; Eisenberger M; Kohli M; Plimack ER; Cooney M; Vogelzang NJ; Picus J; Dipaola R; Sweeney CJ;
J Clin Oncol; 2018 Feb; 36(4):376-382. PubMed ID: 29261442
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast-derived exosomal microRNA regulates NKX3-1 expression in androgen-sensitive, androgen receptor-dependent prostate cancer cells.
Matsuda C; Ishii K; Nakagawa Y; Shirai T; Sasaki T; Hirokawa YS; Iguchi K; Watanabe M
J Cell Biochem; 2023 Aug; 124(8):1135-1144. PubMed ID: 37334663
[TBL] [Abstract][Full Text] [Related]
19. Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.
Kim K; Watson PA; Lebdai S; Jebiwott S; Somma AJ; La Rosa S; Mehta D; Murray KS; Lilja H; Ulmert D; Monette S; Scherz A; Coleman JA
Clin Cancer Res; 2018 May; 24(10):2408-2416. PubMed ID: 29463549
[No Abstract] [Full Text] [Related]
20. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy.
Strum SB; Scholz MC; McDermed JE
Oncologist; 2000; 5(1):45-52. PubMed ID: 10706649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
